Kazakhstan, as the largest economy in Central Asia, faces a significant public health challenge with Cardiovascular Diseases (CVD). According to recent health reports, cardiovascular issues account for nearly 50% of the mortality rate in the country. This has led the Kazakh government to prioritize the development of the pharmaceutical industry through initiatives like the "Salamatty Kazakhstan" health development program. As a leading Cardiovascular Drugs Manufacturer & Supplier, we recognize the critical need for high-purity Active Pharmaceutical Ingredients (APIs) and finished formulations in cities like Almaty, Astana, and Shymkent.
The industrial landscape in Kazakhstan is currently shifting from pure importation to localized manufacturing. While major players like Chimpharm (Santo) and Nobel AFF dominate the local scene, there is a massive vacuum for specialized intermediates and advanced drug delivery systems like drug-eluting microspheres and complex anti-inflammatory injections. Our role as a global supplier is to bridge this gap by providing GMP-certified raw materials that meet the stringent requirements of the Kazakh Ministry of Health.
The pharmaceutical industry in Kazakhstan is clustered primarily in the southern and central regions. Shymkent has emerged as a hub for mass-market generics, while Almaty remains the center for high-tech pharmaceutical R&D and specialized distribution. For Cardiovascular Drugs Manufacturers, the Kazakh market offers a strategic gateway to the broader Eurasian Economic Union (EAEU).
Utilizing the Belt and Road Initiative (BRI), Hangzhou Jeci Biochem Technology ensures a seamless supply chain from China to Kazakhstan. By streamlining logistics through Urumqi and across the Khorgos Gateway, we provide local manufacturers in Kazakhstan with a stable supply of cardiovascular intermediates. This geographic proximity reduces lead times and lowers costs for local drug producers who are under pressure to provide affordable healthcare to the Kazakh population.
Hangzhou Jeci Biochem Technology Co., Ltd. is located in Hangzhou, Zhejiang Province. We are committed to sales of active pharmaceutical ingredients, pharmaceutical intermediates, nutritional products and food additives, cooperative R & D, custom manufacturing, sales and service as well as import of these kinds of materials.
In China, we have a strong collaborative R&D team, working in depth with new drug research institutes and multiple custom processing plants. We have very good domestic sales channels and have long-term relationships with domestic companies, including product applications, technology transfer, product supply, custom processing, and exclusive agents for multiple products in multiple regions. In addition, we also provide factory quality management system certification consulting services.
Drugs and intermediates are widely used in the following aspects (partial):
The next decade for Kazakhstan's cardiovascular sector will be defined by Digitalization and Precision Medicine. We are observing a significant trend toward the use of Drug-Eluting Embolic Microspheres for localized treatments. This technology is particularly relevant for the growing number of advanced surgical procedures being performed in the National Scientific Cardiac Surgery Center in Astana.
Furthermore, the veterinary sector in Kazakhstan—a country with a massive livestock industry—is seeing an increased demand for cardiovascular maintenance in high-value animals. Products like Enalapril for dogs and Allicin-based feed additives are becoming staples for Kazakh veterinary clinics that specialize in livestock health and pet wellness.
We are able to assemble and produce larger quantities of intermediates and provide some advanced, convenient manufacturing capabilities, including batch processing and customization. For the company's main product intermediates: We can maximize our advantages, meet the requirements of most customers and complete the task within the specified time limit.
Our cardiovascular drug portfolio is designed to address specific localized scenarios found in the Central Asian market:
Our international presence extends beyond Central Asia, with long-term trade relations with India, Southeast Asia, South Korea, and Japan. This global perspective allows us to bring world-class quality and innovation to Kazakhstan, supporting local companies with product registration, technology transfer, and sales channel expansion.
Maximize your pharmaceutical manufacturing efficiency in Kazakhstan with our GMP-certified APIs and technical expertise.
Contact Us Today
SJ medical
